New Test Detects Early Signs of Infection After Breast Reconstruction

A new diagnostic tool developed by researchers at Washington University School of Medicine in St. Louis shows promise in detecting infections following breast implant reconstruction weeks before traditional symptoms appear. This advancement could lead to earlier intervention, potentially preserving implants and improving patient outcomes.

The Challenge of Post-Reconstruction Infection

In the United States, approximately one in eight women will be diagnosed with breast cancer in their lifetime, and roughly half will undergo mastectomy.¹ Many patients opt for breast reconstruction, commonly using implants. However, these reconstructions carry a significant risk of infection, often requiring intravenous antibiotics and, in many cases, implant removal.² These complications can lead to additional surgeries, delays in cancer care, increased costs, and emotional distress.

How the New Test Works

Researchers, led by Dr. Jeffrey P. Henderson, a professor in the John T. Milliken Department of Medicine at Washington University, identified specific biomarkers in fluid drained from reconstructed breasts.² These biomarkers appear days or even weeks before clinical signs of infection, such as redness and inflammation, become evident. The study utilized metabolomics, analyzing minor molecules that reflect biochemical activity, to detect both the body’s response to microbial challenges and metabolic products from pathogens.²

Potential Benefits and Clinical Application

The ability to identify infection risk early opens the possibility of proactive surveillance and treatment. Dr. Henderson explained that earlier treatment could be more effective and potentially curative, avoiding prolonged treatment courses, surgery, or implant removal.²

Researchers envision a point-of-care assay integrated into routine post-operative reviews. A positive test result could prompt preemptive antibiotic treatment, even as a negative result could help avoid unnecessary antibiotic use, supporting antibiotic stewardship programs.²

Looking Ahead

Validation studies are needed to confirm the test’s reproducibility across diverse patient populations and surgical settings before widespread use. However, this research represents a significant step toward improving post-mastectomy reconstruction care, potentially reducing complications, preserving reconstruction outcomes, and supporting patient recovery.²